
Anna Sophie Berghoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2097867/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brain tumour cells interconnect to a functional and resistant network. Nature, 2015, 528, 93-98.	13.7	787
2	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
3	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	0.6	485
4	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
5	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncolmmunology, 2016, 5, e1057388.	2.1	239
6	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	0.6	213
7	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	3.9	204
8	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	0.6	191
9	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	9.4	177
10	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open, 2016, 1, e000024.	2.0	152
11	Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin. Cancer Discovery, 2018, 8, 1316-1331.	7.7	123
12	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	3.9	116
13	Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases. Clinical Cancer Research, 2016, 22, 6078-6087.	3.2	109
14	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Journal of Neuro-Oncology, 2016, 130, 19-29.	1.4	107
15	Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clinical and Experimental Metastasis, 2015, 32, 729-737.	1.7	103
16	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, 33, 42-49.		100
17	Tumourâ€infiltrating lymphocytes and expression of programmed death ligand 1 (PD‣1) in melanoma brain metastases. Histopathology, 2015, 66, 289-299.	1.6	99
18	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	0.8	93

#	Article	IF	CITATIONS
19	Characterization of the inflammatory response to solid cancer metastases in the human brain. Clinical and Experimental Metastasis, 2013, 30, 69-81.	1.7	81
20	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. European Radiology, 2017, 27, 3167-3173.	2.3	80
21	New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open, 2019, 4, e000629.	2.0	78
22	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. European Journal of Cancer, 2018, 93, 37-46.	1.3	69
23	<scp>PD</scp> â€l and <scp>PD</scp> â€l expression in <scp>HNSCC</scp> primary cancer and related lymph node metastasis – impact on clinical outcome. Histopathology, 2018, 73, 573-584.	1.6	68
24	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	1.7	66
25	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e116-e122.	1.8	65
26	Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clinical and Experimental Metastasis, 2016, 33, 727-739.	1.7	65
27	New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open, 2019, 4, e000510.	2.0	65
28	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer, 2014, 83, 83-89.	0.9	63
29	High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS ONE, 2018, 13, e0207849.	1.1	63
30	Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. Journal of Neuro-Oncology, 2018, 140, 173-178.	1.4	62
31	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	0.9	59
32	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro-Oncology, 2021, 23, 1100-1112.	0.6	59
33	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast, 2014, 23, 637-643.	0.9	56
34	Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. Journal of Clinical Medicine, 2020, 9, 1272.	1.0	56
35	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	3.9	54
36	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 2016, 18, 401-407.	0.6	53

ANNA SOPHIE BERGHOFF

#	Article	IF	CITATIONS
37	Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. JAMA Oncology, 2022, 8, 106.	3.4	53
38	αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clinical and Experimental Metastasis, 2014, 31, 841-851.	1.7	51
39	The inflammatory microenvironment in brain metastases: potential treatment target?. Chinese Clinical Oncology, 2015, 4, 21.	0.4	51
40	Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathology and Applied Neurobiology, 2015, 41, e41-55.	1.8	49
41	A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treatment Reviews, 2021, 92, 102124.	3.4	44
42	SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. Journal of Clinical Oncology, 2020, 38, 3547-3554.	0.8	40
43	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. Tumor Biology, 2016, 37, 1173-1182.	0.8	39
44	SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO Open, 2020, 5, e000889.	2.0	39
45	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	2.0	38
46	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	1.1	38
47	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer, 2012, 48, 3439-3447.	1.3	37
48	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. European Journal of Cancer, 2015, 51, 1803-1811.	1.3	36
49	Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. Blood, 2021, 137, 1219-1232.	0.6	31
50	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study. European Journal of Cancer, 2022, 165, 184-194.	1.3	29
51	Targeted Therapies for Melanoma Brain Metastases. Current Treatment Options in Neurology, 2017, 19, 13.	0.7	28
52	Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. Cancer Cell, 2022, 40, 444-446.	7.7	28
53	Optimal Management of Brain Metastases from Breast Cancer. CNS Drugs, 2013, 27, 121-134.	2.7	27
54	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases. Cancer, 2020, 126, 4341-4352.	2.0	27

#	Article	IF	CITATIONS
55	Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathology, 2022, 32, e12970.	2.1	27
56	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score. Neuro-Oncology, 2017, 19, now290.	0.6	26
57	Anti-angiogenic therapies inÂbrain metastases. Memo - Magazine of European Medical Oncology, 2018, 11, 14-17.	0.3	26
58	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
59	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. Breast Care, 2014, 9, 134-134.	0.8	25
60	New developments in brain metastases. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878550.	1.5	25
61	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. Journal of Neuro-Oncology, 2020, 148, 187-198.	1.4	25
62	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25
63	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. CNS Oncology, 2015, 4, 47-52.	1.2	24
64	Role of the blood–brain barrier in metastatic disease of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 57-66.	1.0	22
65	LAG-3 expression in the inflammatory microenvironment of glioma. Journal of Neuro-Oncology, 2021, 152, 533-539.	1.4	22
66	Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases. British Journal of Cancer, 2021, 124, 1294-1300.	2.9	21
67	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. Cancers, 2021, 13, 566.	1.7	21
68	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210962.	1.4	21
69	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?. , 2012, 31, 405-408.		19
70	5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO) Tj ETQq0 0 0	rgBT /Ove 1.7	rlock 10 Tf 50
71	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. Journal of Neurosurgery, 2020, 133, 1032-1043	0.9	19

In search of a target: PD-1 and PD-L1 profiling across glioma types. Neuro-Oncology, 2016, 18, 1331-1332. 0.6 18

#	Article	IF	CITATIONS
73	Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. European Journal of Cancer, 2022, 162, 170-181.	1.3	18
74	Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer. Breast Journal, 2013, 19, 149-155.	0.4	17
75	Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. European Journal of Cancer, 2018, 96, 64-72.	1.3	17
76	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open, 2020, 5, e000863.	2.0	17
77	Frequent overexpression of ErbB – receptor family members in brain metastases of nonâ€small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	0.9	15
78	Awareness of predatory journals and open access among medical oncologists: results of an online survey. ESMO Open, 2019, 4, e000580.	2.0	15
79	Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells. Clinical and Experimental Metastasis, 2020, 37, 637-648.	1.7	15
80	Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. BMC Cancer, 2020, 20, 410.	1.1	14
81	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa038.	0.4	14
82	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. Journal of Neuro-Oncology, 2019, 145, 85-95.	1.4	13
83	Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?. Nature Reviews Neurology, 2019, 15, 314-315.	4.9	13
84	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers, 2019, 11, 2020.	1.7	13
85	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. Clinical Journal of Oncology Nursing, 2016, 20, 175-180.	0.3	12
86	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. Cancers, 2021, 13, 603.	1.7	12
87	Atypical sporadic <scp>CJDâ€MM</scp> phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease. Neuropathology, 2015, 35, 336-342.	0.7	11
88	Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. Oncolmmunology, 2018, 7, e1444412.	2.1	11
89	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	3.9	11
90	Venous thromboembolic events in patients with brain metastases: the PICOS score. European Journal of Cancer. 2020, 134, 75-85.	1.3	11

#	Article	IF	CITATIONS
91	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
92	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <scp>cM</scp> et as a negative prognostic factor. Histopathology, 2015, 67, 799-805.	1.6	10
93	Haematopoietic stem cell transplantation for treatment of primary <scp>CNS</scp> lymphoma: singleâ€centre experience and literature review. European Journal of Haematology, 2015, 95, 75-82.	1.1	10
94	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	1.3	10
95	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. Expert Review of Anticancer Therapy, 2021, 21, 325-339.	1.1	10
96	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	2.0	10
97	Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. Journal of Neurology, 2022, 269, 1574-1590.	1.8	10
98	Biology in prevention and treatment of brain metastases. Expert Review of Anticancer Therapy, 2013, 13, 1339-1348.	1.1	9
99	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110090.	1.4	9
100	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care, 2014, 9, 6-6.	0.8	8
101	Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study. Cancer Imaging, 2020, 20, 16.	1.2	8
102	Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	1.7	8
103	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
104	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 351-353.	0.6	7
105	Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit. Palliative and Supportive Care, 2016, 14, 250-258.	0.6	7
106	Postoperative Magnetic Resonance Imaging After Surgery of Brain Metastases: Analysis of Extent of Resection and Potential Risk Factors for Incomplete Resection. World Neurosurgery, 2020, 143, e365-e373.	0.7	7
107	ALKgene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. Apmis, 2014, 122, 867-872.	0.9	6
108	The future of targeted therapies for brain metastases. Future Oncology, 2015, 11, 2315-2327.	1.1	6

#	Article	IF	CITATIONS
109	Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years. Cancers, 2021, 13, 6119.	1.7	6
110	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. Clinical Neuroradiology, 2020, 30, 599-605.	1.0	5
111	Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Translational Oncology, 2022, 19, 101378.	1.7	5
112	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. Palliative and Supportive Care, 2019, 17, 82-86.	0.6	4
113	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. Palliative and Supportive Care, 2020, 18, 33-38.	0.6	4
114	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. ESMO Open, 2020, 5, e000623.	2.0	4
115	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	2.0	4
116	PD1 and PD-L1 expression in glioblastoma Journal of Clinical Oncology, 2014, 32, 2011-2011.	0.8	4
117	Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma Journal of Clinical Oncology, 2020, 38, 2553-2553.	0.8	4
118	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
119	Brain metastases: new systemic treatment approaches. Memo - Magazine of European Medical Oncology, 2021, 14, 198-203.	0.3	3
120	Plasma PD-L1 concentration in patients with brain metastases from solid tumors Journal of Clinical Oncology, 2015, 33, e13026-e13026.	0.8	3
121	EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 1050.	1.8	3
122	SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. Wiener Klinische Wochenschrift, 2021, 133, 909-914.	1.0	2
123	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. Neuro-Oncology Advances, 2021, 3, v35-v42.	0.4	2
124	New Approaches with Precision Medicine in Adult Brain Tumors. Cancers, 2022, 14, 712.	1.7	2
125	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. Wiener Klinische Wochenschrift, 2022, , 1.	1.0	2
126	DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study. Frontiers in Oncology, 2022, 12, 811729.	1.3	2

#	Article	IF	CITATIONS
127	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients Journal of Clinical Oncology, 2014, 32, 1130-1130.	0.8	1
128	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases Journal of Clinical Oncology, 2014, 32, 2012-2012.	0.8	1
129	T-DM1 in HER2-positive breast cancer brain metastases (BM) Journal of Clinical Oncology, 2014, 32, 650-650.	0.8	1
130	A cross-section study evaluating patients' satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria Journal of Clinical Oncology, 2014, 32, e17574-e17574.	0.8	1
131	Correlation of plasma PD-L1 detectability with age in glioma patients Journal of Clinical Oncology, 2015, 33, e13039-e13039.	0.8	1
132	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort Journal of Clinical Oncology, 2016, 34, 2072-2072.	0.8	1
133	ASCO 2021: Highlights in central nervous system tumors. Memo - Magazine of European Medical Oncology, 2021, 14, 323-327.	0.3	1
134	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM) Journal of Clinical Oncology, 2014, 32, 9055-9055.	0.8	1
135	DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, e18527-e18527.	0.8	1
136	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. Anticancer Research, 2020, 40, 6229-6236.	0.5	1
137	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. Neuro-Oncology, 2020, 22, ii129-ii129.	0.6	1
138	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 70-75.	0.3	0
139	41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. Neuro-Oncology Advances, 2020, 2, ii7-ii8.	0.4	0
140	Prognostic factors in leptomeningeal metastases. Neuro-Oncology, 2021, 23, 1208-1209.	0.6	0
141	Systemic and local inflammation characteristics in patients with cancer after lung transplantation Journal of Clinical Oncology, 2021, 39, e14527-e14527.	0.8	0
142	Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. Cancers, 2021, 13, 5050.	1.7	0
143	Correlation of large brain edema with favorable prognosis in patients with single brain metastases Journal of Clinical Oncology, 2012, 30, 2053-2053.	0.8	0
144	Influence of genetic variants of genes potentially associated with colorectal brain metastases on overall survival Journal of Clinical Oncology, 2014, 32, 487-487.	0.8	0

#	Article	IF	CITATIONS
145	Influence of genetic variants of genes potentially associated with brain metastases on overall survival in 70 colorectal cancer patients Journal of Clinical Oncology, 2014, 32, 3565-3565.	0.8	0
146	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases Journal of Clinical Oncology, 2015, 33, e13034-e13034.	0.8	0
147	Prognostic impact of breast cancer (BC) subtype in elderly patients Journal of Clinical Oncology, 2015, 33, e20536-e20536.	0.8	Ο
148	Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases Journal of Clinical Oncology, 2020, 38, 2528-2528.	0.8	0
149	Reply to Stummer, W.; Thomas, C. Comment on "Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)—Experience at Two Specialized Centers. Cancers 2021, 13, 2540― Cancers, 2021, 13, 5705.	1.7	0